Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.

doi:10.1007/s12032-013-0828-9

Article

Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.

Medical oncology (Northwood, London, England) - 1 Feb 2014

Suspitsin Evgeny N, Yanus Grigory A, Sokolenko Anna P, Yatsuk Olga S, Zaitseva Olga A, Bessonov Alexandr A, Ivantsov Alexandr O, Heinstein Valeria A, Klimashevskiy Valery F, Togo Alexandr V, Imyanitov Evgeny N

Abstract excerpt

Somatic inactivation of the remaining allele is a characteristic feature of cancers arising in BRCA1 and BRCA2 mutation carriers, which determines their unprecedented sensitivity to some DNA-damaging agents. Data on tumor-specific status of the involved gene in novel varieties of hereditary breast cancer (BC) remain incomplete. We analyzed 32 tumors obtained from 30 patients with non-BRCA1/2 BC-associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.

Abstract excerpt

Topics

Related research